Translational Biotechnology Hosted Seminar by Mauro Avanzi from Kite Pharma
Building the Future of T Cell TherapiesMauro Avanzi, MD, PhD Medical Director
Wednesday, March 21, 2018 |
||
Dr. Mauro Avanzi is a physician-scientist and adult hematologist-oncologist and currently serves as Medical Director at Kite Pharma. Over the last years Dr. Avanzi has focused his research on developing novel adoptive T cell therapies for the treatment of solid and hematological malignancies. Previously to joining Kite Pharma, Dr. Avanzi held the position of Research Associate at the Memorial Sloan Kettering Cancer Center and conducted research with Chimeric Antigen Receptors (CAR) T cells. Dr. Avanzi was directly involved in developing new immunotherapy-related technologies and bringing these technologies to patients and to the market. Recently, Dr. Avanzi successfully developed a next generation CAR T cell with enhanced anti-tumor effect against hematological and solid tumors. Dr. Avanzi holds a Medical degree from the Campinas University (Brazil), a PhD in stem cell biology from the New York Blood Center and conducted his post-doctoral training studying cancer immunotherapy at the Memorial Sloan Kettering Cancer Center. |